Find Industry reports, Company profilesReportLinker ...
Find Industry reports, Company profilesReportLinker a...
Find Industry reports, Company profilesReportLinker a...
Find Industry reports, Company profilesReportLinker ...
Find Industry reports, Company profilesReportLinker ...
of 5

Polycystic Ovarian Syndrome ' Pipeline Review, H2 2012

Polycystic Ovarian Syndrome ' Pipeline Review, H2 2012 Summary Global Markets Direct's, 'Polycystic Ovarian Syndrome - Pipeline Review, H2 2012', provides an overview of the Polycystic Ovarian Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Polycystic Ovarian Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Polycystic Ovarian Syndrome. 'Polycystic Ovarian Syndrome - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Polycystic Ovarian Syndrome.- A review of the Polycystic Ovarian Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.- Coverage of the Polycystic Ovarian Syndrome pipeline on the basis of route of administration and molecule type.- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.- Key discontinued pipeline projects.- Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Polycystic Ovarian Syndrome.- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.- Devise corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome pipeline depth and focus of Polycystic Ovarian Syndrome therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Published on: Mar 4, 2016
Source: www.slideshare.net


Transcripts - Polycystic Ovarian Syndrome ' Pipeline Review, H2 2012

  • 1. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Polycystic Ovarian Syndrome Pipeline Review, H2 2012Published on August 2012 Report SummaryPolycystic Ovarian Syndrome Pipeline Review, H2 2012SummaryGlobal Markets Directs, Polycystic Ovarian Syndrome - Pipeline Review, H2 2012, provides an overview of the Polycystic OvarianSyndrome therapeutic pipeline. This report provides information on the therapeutic development for Polycystic Ovarian Syndrome,complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in thetherapeutic development for Polycystic Ovarian Syndrome. Polycystic Ovarian Syndrome - Pipeline Review, H2 2012 is built usingdata and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investorpresentations and featured press releases from company/university sites and industry-specific third party sources, put together byGlobal Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicateddisease.Scope- A snapshot of the global therapeutic scenario for Polycystic Ovarian Syndrome.- A review of the Polycystic Ovarian Syndrome products under development by companies and universities/research institutes basedon information derived from company and industry-specific sources.- Coverage of products based on various stages of development ranging from discovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.- Coverage of the Polycystic Ovarian Syndrome pipeline on the basis of route of administration and molecule type.- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & developmentprogress.- Key discontinued pipeline projects.- Latest news and deals relating to the products.Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Polycystic Ovarian Syndrome.- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitiveadvantage.- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.- Devise corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome pipeline depth and focus ofPolycystic Ovarian Syndrome therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects toenhance and expand business potential and scope.- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.Polycystic Ovarian Syndrome Pipeline Review, H2 2012 (From Slideshare) Page 1/5
  • 2. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Table of ContentTable of ContentsTable of Contents 2List of Tables 4List of Figures 4Introduction 5Global Markets Direct Report Coverage 5Polycystic Ovarian Syndrome Overview 6Therapeutics Development 7An Overview of Pipeline Products for Polycystic Ovarian Syndrome 7Polycystic Ovarian Syndrome Therapeutics under Investigation by Universities/Institutes 9Late Stage Products 11Comparative Analysis 11Mid Clinical Stage Products 12Comparative Analysis 12Polycystic Ovarian Syndrome Therapeutics Products under Investigation by Universities/Institutes 13Polycystic Ovarian Syndrome Therapeutics Assessment 14Assessment by Monotherapy Products 14Assessment by Combination Products 15Assessment by Route of Administration 16Assessment by Molecule Type 18Drug Profiles 20Metformin - Drug Profile 20Product Description 20Mechanism of Action 20R&D Progress 20Raloxifene - Drug Profile 22Product Description 22Mechanism of Action 22R&D Progress 22Letrozole - Drug Profile 24Product Description 24Mechanism of Action 24R&D Progress 24Human Chorionic Gonadotropin + Clomiphene Citrate - Drug Profile 25Product Description 25Mechanism of Action 25R&D Progress 25D-chiro-inositol - Drug Profile 27Product Description 27Mechanism of Action 27R&D Progress 27Simvastatin - Drug Profile 28Product Description 28Mechanism of Action 28Polycystic Ovarian Syndrome Pipeline Review, H2 2012 (From Slideshare) Page 2/5
  • 3. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!R&D Progress 28Medroxyprogesterone - Drug Profile 29Product Description 29Mechanism of Action 29R&D Progress 29Polycystic Ovarian Syndrome Therapeutics Drug Profile Updates 30Polycystic Ovarian Syndrome Therapeutics - Dormant Products 31Appendix 33Methodology 33Coverage 33Secondary Research 33Primary Research 33Expert Panel Validation 33Contact Us 34Disclaimer 34List of TablesNumber of Products Under Development for Polycystic Ovarian Syndrome, H2 2012 7Products under Development for Polycystic Ovarian Syndrome Comparative Analysis, H2 2012 8Number of Products under Investigation by Universities/Institutes, H2 2012 10Comparative Analysis by Late Stage Development, H2 2012 11Comparative Analysis by Mid Clinical Stage Development, H2 2012 12Products under Investigation by Universities/Institutes, H2 2012 13Assessment by Monotherapy Products, H2 2012 14Assessment by Combination Products, H2 2012 15Assessment by Stage and Route of Administration, H2 2012 17Assessment by Stage and Molecule Type, H2 2012 19Polycystic Ovarian Syndrome Therapeutics Drug Profile Updates 30Polycystic Ovarian Syndrome Therapeutics Dormant Products 31Polycystic Ovarian Syndrome Therapeutics Dormant Products (Contd..1) 32List of FiguresNumber of Products under Development for Polycystic Ovarian Syndrome, H2 2012 7Products under Development for Polycystic Ovarian Syndrome Comparative Analysis, H2 2012 8Products under Investigation by Universities/Institutes, H2 2012 9Late Stage Products, H2 2012 11Mid Clinical Stage Products, H2 2012 12Assessment by Monotherapy Products, H2 2012 14Assessment by Combination Products, H2 2012 15Assessment by Route of Administration, H2 2012 16Assessment by Stage and Route of Administration, H2 2012 17Assessment by Molecule Type, H2 2012 18Assessment by Stage and Molecule Type, H2 2012 19Polycystic Ovarian Syndrome Pipeline Review, H2 2012 (From Slideshare) Page 3/5
  • 4. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Polycystic Ovarian Syndrome Pipeline Review, H2 2012 Product Formats Please select the product formats and the quantity you require. 1 User License--USD 2 000.00 Quantity: _____ Site License--USD 4 000.00 Quantity: _____ Corporate License--USD 6 000.00 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________Polycystic Ovarian Syndrome Pipeline Review, H2 2012 (From Slideshare) Page 4/5
  • 5. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93Polycystic Ovarian Syndrome Pipeline Review, H2 2012 (From Slideshare) Page 5/5

Related Documents